AAMU
ANAB icon

Amundi Asset Management US’s AnaptysBio ANAB Stock Holding History

Amundi Asset Management US’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,500
Closed -$85K – 1622
2019
Q2 		$85K Hold
1,500
– – ﹤0.01% 1583
2019
Q1 		$110K Buy
+1,500
New +$104K ﹤0.01% 1544

Other funds holding ANAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Amundi Asset Management US's ANAB Position: Q3 2019 in Review

Amundi Asset Management US sold out of AnaptysBio (ANAB) in Q3 2019, closing a stake of 1,500 shares — an estimated $85K sold.

Amundi Asset Management US first reported a position in ANAB in Q1 2019 and held it in 2 quarters. The position peaked at $110K in Q1 2019. 119 funds tracked by Wall St. Rank hold ANAB as of Q3 2019.

  • Amundi Asset Management US reported no remaining AnaptysBio position as of Q3 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 1,500 AnaptysBio shares in Q3 2019, an estimated $85K.
  • Amundi Asset Management US first reported a position in AnaptysBio in Q1 2019 and held it in 2 quarters.
  • Amundi Asset Management US's AnaptysBio position peaked at $110K in Q1 2019.
  • 119 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2019.

Based on Amundi Asset Management US's 13F filing for Q3 2019, filed 14 Nov 2019.